NORTHWEST BIOTHERAPEUTICS INC (NWBO)
CIK 1072379 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 1.71B shares as of Aug 13, 2026 (10-Q).⊙
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Warrants Issued As Consideration For Warrants Suspension | 91.0M | not tagged | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 14, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 91.2M underlying shares, as reported Jun 30, 2026 (10-Q).
Reported exercise price: $0.24 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $300,000 as of Jun 5, 2017.
Rough fully diluted estimate: 1.80B = 1.71B O/S + 91.2M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| March Convertible Notes | $5.0M | — | not tagged | 9% | — |
| Long Term Convertible Notes At Fair Value | $3.0M | $2.9M | $0.19 | 0%-11% | ~15.8M sh |
| Long Term Convertible Notes Payable | $2.4M | $2.4M | $0.21 | 11% | ~11.3M sh |
| Short Term Convertible Notes At Fair Value | $2.0M | $2.1M | $0.19 | 0%-12% | ~10.5M sh |
| January Convertible Notes | $1.0M | — | $0.25 | 11% | ~4.0M sh |
| Additional Convertible Note | $800,000 | — | $0.5 | — | ~1.6M sh |
| Short Term Debt | $135,000 | $135,000 | $3.09 | 6%-8% | ~43,689 sh |
| Convertible Notes At Fair Value | not tagged | — | $0.2 | — | — |
If every note above converted at its tagged price: ~43.2M new shares on 1.71B currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 14, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 1.71B | Aug 13, 2026 |
| + Warrants Issued As Consideration For Warrants Suspension (if exercised) | 91.0M | Jun 30, 2026 |
| + Long Term Convertible Notes At Fair Value (if fully converted) | 15.8M | Jun 30, 2026 |
| + Long Term Convertible Notes Payable (if fully converted) | 11.3M | Jun 30, 2026 |
| + Short Term Convertible Notes At Fair Value (if fully converted) | 10.5M | Jun 30, 2026 |
| + January Convertible Notes (if fully converted) | 4.0M | Jan 26, 2026 |
| + Additional Convertible Note (if fully converted) | 1.6M | Jan 26, 2026 |
| + Short Term Debt (if fully converted) | 43,689 | Jun 30, 2026 |
| Fully diluted estimate | 1.84B | +7.9% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $250.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 2 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full NWBO workspace
Free to use. No account, no card.